There is extensive collaboration between City of Hope clinicians and researchers to develop and evaluate new colorectal cancer therapies designed to improve survival and quality of life outcomes. City of Hope patients have access to a wide variety of clinical trials ranging from new chemotherapy and targeted therapies, novel surgical techniques and new radiation approaches — all focused on enhancing treatment, detection and prevention of colorectal cancer.
Some of our current research projects:
City of Hope is part of a trial testing the drugs sulindac (Clinoril®) or eflornithine (Ornidyl®) (or the combination of the two) and its impact on colorectal cancer recurrence. In previous studies, the two drug combination has been shown to significantly reduce polyp development, but this hasn’t been compared to the effectiveness of either drug alone. The results of this trial will help determine which drug regimen will be ideal for the chemoprevention of colorectal cancer, and to lead to a better understanding of how these drugs work alone and together against colorectal cancer.
At City of Hope, patients with metastatic colorectal cancer have the opportunity to enroll in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Patient Registry and Biospecimen Profiling Repository, in which their cancer tissues can be molecularly profiled for genetic abnormalities and other biomarkers. This helps researchers better understand the mechanisms of the cancer, and enrolled patients may be able to participate in appropriate NSABP studies for novel treatments (such as drugs that are only effective against cancer cells with a specific gene mutation.)
Several cancers, including colorectal cancer, are linked to a mutation of the BRAF gene, which drives uncontrolled cell growth by producing an abnormal version of the BRAF protein. City of Hope is currently testing an investigational new drug, CEP-32496, that may be able to block this protein. If successful, this can add a new drug to treat BRAF-linked colorectal cancer, as well as melanoma, thyroid, ovarian and lung cancers.